CalciMedica (CALC) Anticipates Key Phase 2 Data Readout in 2026 with $14.1M Cash Position
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
Source: NASDAQ.COM
- Clinical Trial Progress: CalciMedica's ongoing KOURAGE trial evaluating Auxora for acute kidney injury (AKI) is set to release key data in the first half of 2026, potentially providing significant support for the company's future development.
- FDA Trial Design Discussions: The company has engaged in positive discussions with the FDA regarding the pivotal trial design for acute pancreatitis (AP), with the final design expected in 1H 2026, laying the groundwork for subsequent clinical trials.
- Strong Financial Position: As of September 30, 2025, CalciMedica reported cash and short-term investments totaling $14.1 million, which is anticipated to fund operations into the second half of 2026, ensuring continuity in research and development activities.
- Stock Price Fluctuation: CALC's stock has traded between $1.42 and $7.20 over the past year, closing yesterday at $5.60, up 9.16%, and further rising to $5.78 in after-hours trading, reflecting market optimism regarding its future prospects.
Analyst Views on CALC
Wall Street analysts forecast CALC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CALC is 20.00 USD with a low forecast of 20.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.120
Low
20.00
Averages
20.00
High
20.00
Current: 5.120
Low
20.00
Averages
20.00
High
20.00
About CALC
CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase IIb trial (called CARPO) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase I/II asparaginase-induced pancreatic toxicity (AIPT) study (called CRSPA).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
